On 29 July 2016, the Japan News by the Yomiuri Shinbun reported that the transplant of iPS cells has been approved in Kobe.
The ethics committee of the Kobe City Medical Center General Hospital has approved a surgery plan to transplant retina developed from donor-derived induced pluripotent stem (iPS) cells to an eye-disease patient. The hospital in Kobe will aim to carry out the surgery, part of the world’s first clinical study of iPS cells, in the first half of 2017, after getting the green light from the government.
The subject of the treatment will be a patient with age-related macular degeneration, a serious disease that can lead to blindness. The Riken Center for Developmental Biology, or CDB, will generate retina from iPS cells, supplied by Kyoto University’s Center for iPS Cell Research and Application, from donors with no blood ties to the patient.